Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update

Initiation of two clinical trials of SON-1010 in both healthy volunteers and patients with advanced solid tumorsPositive preclinical data of SON-1010 combined with anti-PD1 Checkpoint InhibitionSubsequent Events During The Fiscal Year 2022 Fourth …